Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination : protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study by Simpson, Colin R et al.
Simpson, Colin R and Lone, Nazir I and Kavanagh, Kimberley and 
Robertson, Chris and McMenamin, Jim and von Wissmann, Beatrix and 
Vasileiou, Eleftheria and Butler, Chris and Ritchie, Lewis D and Gunson, 
Rory and Schwarze, Jürgen and Sheikh, Aziz (2017) Evaluating the 
effectiveness, impact and safety of live attenuated and seasonal 
inactivated influenza vaccination : protocol for the Seasonal Influenza 
Vaccination Effectiveness II (SIVE II) study. BMJ Open, 7 (2). ISSN 2044-
6055 , http://dx.doi.org/10.1136/bmjopen-2016-014200
This version is available at http://strathprints.strath.ac.uk/60171/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (http://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Evaluating the effectiveness, impact
and safety of live attenuated and
seasonal inactivated inﬂuenza
vaccination: protocol for the Seasonal
Inﬂuenza Vaccination Effectiveness II
(SIVE II) study
Colin R Simpson,1 Nazir I Lone,1 Kimberley Kavanagh,2 Chris Robertson,2,3
Jim McMenamin,3 Beatrix von Wissmann,3 Eleftheria Vasileiou,1 Chris Butler,4,5
Lewis D Ritchie,6 Rory Gunson,7 Jürgen Schwarze,8 Aziz Sheikh1
To cite: Simpson CR,
Lone NI, Kavanagh K, et al.
Evaluating the effectiveness,
impact and safety of live
attenuated and seasonal
inactivated influenza
vaccination: protocol for the
Seasonal Influenza
Vaccination Effectiveness II
(SIVE II) study. BMJ Open
2017;7:e014200.
doi:10.1136/bmjopen-2016-
014200
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-014200).
Received 9 September 2016
Revised 28 November 2016
Accepted 12 January 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Colin R Simpson;
c.simpson@ed.ac.uk
ABSTRACT
Introduction: Seasonal (inactivated) influenza
vaccination is recommended for all individuals aged
65+ and in individuals under 65 who are at an increased
risk of complications of influenza infection, for example,
people with asthma. Live attenuated influenza vaccine
(LAIV) was recommended for children as they are
thought to be responsible for much of the transmission
of influenza to the populations at risk of serious
complications from influenza. A phased roll-out of the
LAIV pilot programme began in 2013/2014. There is
limited evidence for vaccine effectiveness (VE) in the
populations targeted for influenza vaccination. The aim
of this study is to examine the safety and effectiveness
of the live attenuated seasonal influenza vaccine
programme in children and the inactivated seasonal
influenza vaccination programme among different age
and at-risk groups of people.
Methods and analysis: Test negative and cohort
study designs will be used to estimate VE. A primary
care database covering 1.25 million people in Scotland
for the period 2000/2001 to 2015/2016 will be linked to
the Scottish Immunisation Recall Service (SIRS), Health
Protection Scotland virology database, admissions to
Scottish hospitals and the Scottish death register.
Vaccination status (including LAIV uptake) will be
determined from the primary care and SIRS database.
The primary outcome will be influenza-positive real-time
PCR tests carried out in sentinel general practices and
other healthcare settings. Secondary outcomes include
influenza-like illness and asthma-related general practice
consultations, hospitalisations and death. An
instrumental variable analysis will be carried out to
account for confounding. Self-controlled study designs
will be used to estimate the risk of adverse events
associated with influenza vaccination.
Ethics and dissemination: We obtained approval
from the National Research Ethics Service Committee,
West Midlands—Edgbaston. The study findings will be
presented at international conferences and published in
peer-reviewed journals.
Trial registration number: ISRCTN88072400; Pre-
results.
INTRODUCTION
Globally, it is estimated that seasonal inﬂu-
enza is responsible for ﬁve million cases of
severe illness and 500 000 deaths per year,
with an estimated cost to the USA of $87
billion per annum.1 2 Worldwide, there
are an estimated 90 million new cases of
inﬂuenza and 1 million cases of inﬂuenza-
associated severe acute lower respiratory
infection among children.3 National inﬂu-
enza vaccination programmes delivered by
primary care in the community are import-
ant for reducing inﬂuenza-related illness,
hence the considerable investment in this
approach. These programmes previously tar-
geted only older people (65+ years) and
people considered at risk with chronic dis-
eases, for example, asthma who are
Strengths and limitations of this study
▪ The study population comprises a large, repre-
sentative sample of the general population.
▪ We are developing a large national linked data-
base, which contains anonymised individual
patient-level data from general practices, hospi-
tals, virology (real-time PCR) investigations and
the death register.
▪ This is an observational study using routinely
collected data, and therefore residual confound-
ing may still be present or unaccounted for. We
will measure the levels of unknown confounding
required to impact on our study results.
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particularly susceptible to becoming seriously ill when
they get inﬂuenza.
Children are important in the transmission of inﬂu-
enza to the populations at risk of serious complications
from inﬂuenza and diminished circulation of virus has
been predicted to improve herd immunity.4 Using evi-
dence generated from epidemiological modelling,5 and
following advice from the Joint Committee for
Vaccination and Immunisation6 from September 2013,
the seasonal inﬂuenza vaccination programme has been
extended. In addition to the seasonal trivalent and
quadrivalent inactivated inﬂuenza vaccine for at-risk
individuals and those aged 65+ years, the live attenuated
inﬂuenza vaccine (LAIV) is offered to all children aged
2–17 years (except those severely immunodeﬁcient or
those with severe asthma, prescribed immunosuppressive
therapy or oral steroids) by primary care clinicians in
general practice and schools in Scotland.
Clinical trials have found beneﬁts of LAIV in healthy
children under 7 years of age (most for under 3 years
old).7 8 Efforts to estimate seasonal inactivated inﬂuenza
vaccine effectiveness (VE) have been largely conﬁned to
younger, healthy adults (with few clinical trials showing
efﬁcacy in 65+ years and those with chronic disease).9–11
Recent observational studies have attempted to estimate
the VE in preventing inﬂuenza-related illness in general
practice patients.12 Further studies have examined VE
with hospitalisation or death, however they have suffered
from bias when using non-speciﬁc outcomes,7 or have
been underpowered when using more speciﬁc end points
such as laboratory-conﬁrmed inﬂuenza, in particular for
subgroups being targeted for vaccination (eg, 65+ years
and people with at-risk disease such as asthma and preg-
nant women),13 cohort studies (with nested case–control
studies) or data linkage-derived estimates of VE have
been undertaken with measures taken to overcome many
of the confounding issues that otherwise have limited esti-
mations of effectiveness.14–16 There is also a need to add
to the growing body of evidence with regard to the safety
of these vaccines.17 Given the ongoing controversy regard-
ing VE and in particular in relation to at-risk groups such
as those with asthma,7 and the interim recommendation
by the Advisory Committee on Immunization Practices
(ACIP) not to use the LAIV in the USA during the 2016/
2017 seasons,18 there is further need for information to
help evaluate new policies regarding seasonal vaccine
strategies.
This research aims to examine the VE and safety of
the seasonal inﬂuenza vaccines including LAIV and the
inactivated inﬂuenza vaccine. We will have access to a
unique set of linked databases within a trusted research
environment (TRE), which will contain individual
patient-level data relating to primary healthcare, acute
hospital care, school immunisation data, virological real-
time PCR (RT-PCR) laboratory tests and mortality. In
contrast to previous observational studies, these richer
data sources will provide information on a large number
of potential confounders and highly speciﬁc laboratory
outcome measures in a study cohort sampled from the
general population. Our assessment of the effectiveness
and the public health impact of a new seasonal inﬂu-
enza vaccination programme seeks to clarify whether
such a programme leads to societal beneﬁts, therefore
advancing the international evidence base. More specif-
ically, the objectives of this study are to: (1) provide an
estimate of the uptake and VE of LAIV administered to
children (introduced to the national vaccination pro-
gramme in 2013); (2) evaluate seasonal inﬂuenza VE in
at-risk groups (eg, 65+ years, people with asthma, people
with other comorbidities and pregnant women); and (3)
measure adverse events associated with vaccination.
METHODS
Study design and population
Vaccine uptake will be reported using serial cross-
sectional surveys of each inﬂuenza season. The test-
negative design (TND)19 will be used to measure VE for
the RT-PCR outcomes and a cohort study design for
non-speciﬁc clinical outcomes, for example, hospitalisa-
tion or death from inﬂuenza or pneumonia.
We will seek to extract data on up to 1.25 million
people in Scotland by recruiting 220 general practices
into our study. Each patient will contribute person-time
to each inﬂuenza season while alive and registered with
a participating general practice.
Databases
Data ﬁelds extracted from the following databases will be
linked deterministically using the Community Health
Index (CHI) number—a unique identiﬁer used by the
National Health Service (NHS) for the Scottish popula-
tion. The database linkage and analysis will occur within
the National Services Scotland (NSS) TRE by the elec-
tronic Database Research and Innovation Service (eDRIS).
General practice: Almost all individuals resident in
Scotland are registered with a general practice, which
provides healthcare services free of charge. Virtually all
specialist hospital care services are also free of charge,
usually obtained through referral from primary care or,
in emergency situations, through patients attending an
accident and emergency department. Primary care-
based physicians coordinate the inﬂuenza vaccination
programme for their patients and provide much of the
care of patients discharged back into the community by
secondary and tertiary care services. Completeness of
capture of contacts and accuracy of clinical event coding
(using Read codes) has been found to be above 91%
among practices in Scotland.20 21 The electronic record-
ing of long-term prescribing information by primary
care has also been found to be accurate and complete.22
Scottish Immunisation Recall System: The Scottish
Immunisation Recall System (SIRS) is a database that
has a record of all children (used nationally from 2002)
with scheduled vaccinations. Data on vaccination admin-
istration for all children in Scotland are also recorded
2 Simpson CR, et al. BMJ Open 2017;7:e014200. doi:10.1136/bmjopen-2016-014200
Open Access
here.23 These data will be used to determine inﬂuenza
vaccinations that have been administered in schools
rather than in primary care.
Electronic Communication of Surveillance in Scotland: Data
on more than 60 000 RT-PCR tests in total (including an
additional 1500 tests per season funded to target 2-year
and 3-year olds) have been collated into the Electronic
Communication of Surveillance in Scotland (ECOSS)
database which is used for the identiﬁcation of severe
disease, outbreaks and long-term trends in the incidence
of laboratory-reported infections.24
Scottish Morbidity Record: The Information Services
Division (ISD) maintains a database of all acute hospital
discharges and deaths in Scotland, known as the Scottish
Morbidity Record 1 (SMR01). All inpatient and day case
episodes of care for acute hospitals since 1981 have
been recorded in the database. The database is subject
to regular validation checks, and the most recent quality
assurance report indicated good levels of accuracy
(>90%) for the ﬁelds used in this study.25 Diagnostic
information is recorded using the International
Classiﬁcation of Disease V.10 (ICD-10). There are up to
six ﬁelds the can be used to record diagnoses, with one
allocated as the main reason for admission. SMR01 is
linked routinely by ISD to the Scottish death register
using patient characteristics in a probabilistic matching
algorithm with a high degree of accuracy.26 Details from
death certiﬁcates issued for all deaths in Scotland are
recorded in the death register, maintained by National
Records Scotland (NRS).27 Cause of death has been rou-
tinely coded using ICD-10 since 2000.
Study period
Data from 1 September 2000 to 31 August 2016 will be
used. This will allow analysis of 16 inﬂuenza seasons
(2000/2001 to 2015/2016). Each patient will contribute
person-time to each inﬂuenza season while alive and regis-
tered with a participating general practice. For the non-
pandemic seasons, each year (1 September to 31 August)
will be divided in to four periods (ﬁgure 1). The inﬂuenza
season will be deﬁned for each year using national inﬂu-
enza surveillance data.28 The other periods will include a
preinﬂuenza season (starting 1 September), a
postinﬂuenza period, which will end 31 May each year and
a ‘non-inﬂuenza’ period from 1 June to 31 August (ﬁgure
1). In the prepandemic year 2008/2009, there will be no
non-inﬂuenza period in the summer. The introduction of
the inﬂuenza vaccination programme for children was
phased over successive seasons. Therefore, in season 2013/
2014 we will analyse data for children aged 2 and 3 years
and those attending primary schools (where pilots were
taking place) across Scotland; in seasons 2014/2015 and
2015/2016, we will analyse data for all preschool children
aged 2–4 years and all primary school age children (ie, all
children aged 2–11).
Exposure definition
For people in at-risk groups, inﬂuenza vaccinations
(Trivalent Inﬂuenza Vaccine (TIV) and LAIV for pre-
school children aged ≥2 years) are free and adminis-
tered by general practice.29 Data on inﬂuenza
vaccination carried out in general practice (including
CHI and date of administration) are recorded to enable
reimbursement. Information on individuals receiving
LAIV in schools is collated in the SIRS database and will
be extracted for this analysis.21 Vaccination will be used
to deﬁne exposure status if it is given at a time point
between 1 September and the end of the inﬂuenza
season (ﬁgure 1). An individual will be deﬁned as vacci-
nated 14 days after the seasonal inﬂuenza vaccine has
been administered.30 The time period from the ﬁrst day
of the inﬂuenza season to day 14 postvaccination will be
deﬁned as ‘unexposed’ and the period from day 14 post-
vaccination until the end of the inﬂuenza season will be
deﬁned as ‘exposed’. Therefore, those vaccinated
between the start of the preinﬂuenza period up until
14 days before the inﬂuenza season will be deﬁned as
‘exposed’ for the duration of the inﬂuenza season. We
will exclude participants vaccinated <14 days prior to the
RT-PCR test as a sensitivity analysis.
Patient characteristics and confounding factors
Key characteristics of patients present in each season of
the cohort will be included as confounders in the ana-
lyses. Confounders will be deﬁned in each year on the
ﬁrst day of the preinﬂuenza season (1 September).
Figure 1 Relationship of first influenza season (2000–2001) to preinfluenza, postinfluenza and non-influenza season periods.
Baseline characteristics for each patient are determined on 1 September each year. The earliest date of influenza vaccination
varied for each influenza season, but always occurred after 1 September.
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Demographics: Sex, age band and socioeconomic status
will be included in all analyses; socioeconomic status will
be measured using quintiles of the Scottish Index of
Multiple Deprivation (SIMD). SIMD is an area-based
measure of deprivation derived from seven domains
including income, employment and education.31
Rurality in terms of urban/rural location (one large
urban, six remote rural) will also be included in the
analysis.
At-risk groups: At-risk patients are those with certain
comorbidities for whom seasonal inﬂuenza vaccination
is indicated. Patients will be deﬁned as high risk accord-
ing to national guidance29 if they have one or more of
the following conditions:
▸ Asthma;
▸ Chronic heart disease;
▸ Chronic kidney disease (including renal transplant-
ation) stages 1–2 and 3–5;
▸ Chronic liver disease;
▸ Chronic neurological diseases;
▸ Chronic respiratory diseases;
▸ Conditions or drugs causing impaired immune
function;
▸ Diabetes;
▸ Pregnancy (from 2009/2010);
▸ Asplenia or dysfunction of the spleen
(from 2014/2015);
▸ Body mass index (for 2015/2016).
Chronic diseases: We will include this for our non-
speciﬁc clinical outcomes and adverse events.
Comorbidity will be deﬁned by the 17 disease categories
that constitute the Charlson Comorbidity Index.32 This
Index has been validated in a number of different data-
bases using codes from healthcare databases.33
Furthermore, a study has mapped Read codes from a
UK general practice database to the relevant Charlson
comorbid disease groups, resulting in a model that per-
formed well in the prediction of 5-year mortality.34
These codes will be used to identify comorbidities that
are present in a patent’s record prior to the start of each
preinﬂuenza season (1 September).
Smoking status: This will be derived from primary care
data (current smoker, ex-smoker, non-smoker) and
determined on 1 September each year.
Previous vaccinations: A variable will be included for
patients who have received seasonal inﬂuenza vaccin-
ation in previous seasons to account for the possibility of
persisting or reduced VE in the subsequent year.35 36
Adjustment for previous pneumococcal vaccination at
any time in the primary care record prior to 1
September each year will also be undertaken.
Previous healthcare usage: Measures of previous health-
care resource use will also capture other aspects of
chronic health status and include previous years general
practitioner (GP) consultations, prescriptions (repeat)
and number of admissions to hospital.
Functional status: There is no direct measure of func-
tional status made in any of these national databases.
However, individuals who are resident in some form of
institutional care setting can be identiﬁed from the
primary care database. This will also be used as an indi-
cator of more severe functional limitation.
Practice: Accounting for the clustering of patients
within GP practices, we will investigate whether practice
characteristics (eg, training practice, list size, type of con-
tract, etc) are associated with vaccine uptake.
Studies
RT-PCR study
We will target the recruitment of primary care practices
involved in the Health Protection Scotland (HPS)
Pandemic Inﬂuenza Primary Care Reporting (PIPER)
sentinel-swabbing scheme, whereby practices are encour-
aged to obtain nasal/throat swabs from patients of all
ages who have symptoms suggestive of inﬂuenza. Each
general practice is requested to submit ﬁve swab samples
per week (seven from season 2015/2016) to the West of
Scotland Specialist Virology Centre (WoSSVC), Glasgow
Royal Inﬁrmary, Glasgow, UK for RT-PCR testing for a
range of respiratory pathogens on any patient presenting
for consultation in the practice with inﬂuenza symptoms
across all ages independent of whether the patient has
or has not been vaccinated. Data are also collated by
HPS on RT-PCR testing patients from swabbing carried
out in primary and secondary care for routine diagnostic
purposes outside the sentinel scheme. All RT-PCR data
on positive and negative tests are held by HPS in the
national laboratory database—ECOSS database. WoSSVC
is a WHO accredited National Inﬂuenza Center, which
participates in the quality assurance programme to
maintain this status. From 1999, the RT-PCR testing used
to conﬁrm respiratory virus type has been found to be
highly sensitive for inﬂuenza A (H3, H1) and B diagno-
sis.37 Improvements to RT-PCR since 2003 include the
development of multiplex testing increasing the number
of pathogens tested per PCR assay, however the high sen-
sitivity of these tests remain unchanged.38
Non-specific clinical outcomes study
To determine the effect of vaccination status on
inﬂuenza-related primary care consultations, hospital
admissions and deaths, secondary analyses will be under-
taken using non-speciﬁc clinical outcomes derived from
primary and secondary care. Inﬂuenza-like illness (ILI)
and otitis media consultation will be derived from the
general practice database. Hospitalisation and cause of
death from inﬂuenza or pneumonia will be derived
from SMR01. We will also include in our secondary ana-
lysis a range of asthma-related outcomes, for example,
asthma-related consultations/symptoms or measure-
ments, hospitalisations/deaths, rescue medications, etc.
Unmeasured confounding and instrumental variable analyses
In addition to Simonsen’s Framework, we will also assess
the robustness of our results by modelling the effect of
an unmeasured confounder on our VE estimates in
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sensitivity analyses, an approach used previously39 and
being widely adopted to help explain the role of
unknown confounding in observational analyses.40 We
will vary three factors: the prevalence of the confounder
in the vaccinated population, its prevalence in the
unvaccinated population and the increased risk of the
outcome attributable to the confounder.41 The use of
inﬂuenza vaccine coverage by geographical area has
been found to be a strong and valid instrumental vari-
able (IV), which can be used to account for confound-
ing.42 Rather than compare patients with respect to
whether they received inﬂuenza vaccination, this IV
behaves like natural randomisation of patients to
regional vaccination groups that differ in their likeli-
hood of receiving inﬂuenza vaccination. The NSS TRE is
an important development in this respect, and we have
received permissions to extract granular postcode/geo-
coding data required to test the validity of this IV analysis
in the SIVE II database. We will therefore explore the
suitability of vaccination uptake in geographically dis-
tinct Health and Social Care Partnership areas or other
suitable Health Board areas as a suitable IV. To be valid,
this IV needs to be related to exposure status (ie, vaccin-
ation status) and not have an independent effect on
outcome other than by ways mediated through the
exposure.43 Furthermore, the IV should not be related
to any variables that confound the relationship between
exposure and outcome. If an association with confoun-
ders is demonstrated, it is assumed that the IV is asso-
ciated with unmeasured confounders and is therefore
not valid. If the IV fulﬁls these criteria, it can be used in
analyses to produce unbiased estimates of VE by
accounting for unmeasured confounding.
Adverse events associated with vaccination study
We will explore the use of self-controlled study designs
to estimate the risk of adverse events following inﬂuenza
vaccination.44 The assumption underlying these designs
is that, in the situation where the adverse event is related
to vaccination, the occurrence of an adverse event in the
period after vaccination is greater than periods in the
same patient that are temporally unrelated to vaccin-
ation.45 These methods have the advantage of control-
ling for all ﬁxed individual-level confounders as
comparisons are within the same individual rather than
between vaccinated and unvaccinated populations. The
time period at risk for an adverse event (risk interval)
and time period not at risk (control interval) will be
determined separately for each outcome.46
Statistical analysis
Baseline characteristics will be summarised by vaccin-
ation status for the whole cohort using mean, median or
proportion where appropriate together with a measure
of dispersion. We will evaluate the baseline character-
istics of those tested and not tested using RT-PCR.
Missing data will be reported for each variable. A 5% sig-
niﬁcance level will be used for hypothesis tests for the
primary outcome. All p values will be two sided. All ana-
lyses will be undertaken in R (V.3.2.3; R Core Team
(2015). R: A language and environment for statistical
computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org).
Annual and pooled analyses
We will initially analyse each of the 16 inﬂuenza seasons
separately for the primary outcome. However, a pooled
analysis will be performed if increased precision is
required (particularly for less common outcomes or
where analysing subgroups of patients). We will test the
heterogeneity of the vaccine effect over the seasons, by
testing for interaction between vaccine status and year
for the outcomes. If appropriate, we will then pool the
data to give a more powerful analysis than the stratiﬁed
results. Where heterogeneity occurs, however, the
pooled analysis can be restricted or abandoned. In this
pooled analysis, we will account for the within-person
correlation resulting from repeated measures on the
same individual in different inﬂuenza seasons.
Vaccine uptake
Vaccine uptake will be modelled through logistic regres-
sion. ORs (adjusted for age, sex, clinical risk group and
deprivation) for differences in proportion of vaccine
uptake between different groups of patients (eg, sex,
age, SIMD categories and at-risk groups) and for investi-
gating trends in vaccine uptake will be calculated.
Vaccine uptake and 95% CIs will be calculated. Practice
characteristics will be incorporated by using a multilevel
approach.
Vaccine effectiveness
RT-PCR outcomes
For VE using information from linked virological
RT-PCR swab data (a binary event) we will carry out a
nested case test-negative control study.19 Inﬂuenza posi-
tivity will be compared with no inﬂuenza among patients
who have ILI symptoms and tested for inﬂuenza. The
primary analysis will be through a logistic generalised
additive model where the effects of gender, age, socio-
economic status (SIMD33) and being in an at-risk mor-
bidity group are adjusted for (a TND study). A spline
function for time during each season will be included to
model the background rate of inﬂuenza and correct for
any potential bias associated with the proportions of test-
negative and test-positive patients at different periods.
VE will be measured by comparing the results from
swabs taken after vaccination among those vaccinated to
swabs taken among those unvaccinated at the time the
swab is collected. Vaccination will be used to deﬁne
exposure status if it was given at a time point between
the 1 September and the end of the inﬂuenza season
(ﬁgure 1). The adjusted estimate of VE=(1−OR)×100,
where the OR is derived from the coefﬁcient of vaccine
status in the model. In our main analysis, we will
assess only the ﬁrst dose when two doses are given. We
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will carry out analysis stratiﬁed by inﬂuenza A
(H1—including pandemic inﬂuenza and H3 subtype
where recorded) and B.
We will carry out a number of sensitivity analyses for the
primary end point:
1. Non-sentinel versus sentinel: We will explore the validity
of using laboratory-conﬁrmed inﬂuenza tests from
non-sentinel primary care and secondary care
sources versus sentinel primary care practices. Patient
characteristics of individuals swabbed in non-sentinel
primary care practices and secondary care will be
described and any interaction between source of
swab and outcome will be tested.
2. Negative controls: As there should be no VE for inﬂu-
enza vaccine for these outcomes, we will explore the
use of laboratory-conﬁrmed infections (currently 10
respiratory viruses including rhinovirus and adeno-
virus) tested using multiplex RT-PCR at the same
time as the inﬂuenza RT-PCR.
3. LAIV VE in younger/immunodeﬁcient: For younger
vaccine-naïve or immunodeﬁcient children receiving
LAIV, we will account for any second dose in our
model.
Non-specific clinical outcomes
We will estimate VE for non-speciﬁc clinical outcomes:
primary care consultations for ILI; all-cause emergency
hospitalisation and death; and emergency hospitalisation
and death due to inﬂuenza/pneumonia. Hospital admis-
sions and consultations can have multiple events and
each event will be counted.
For this proposal we have adopted methods we found
in previous studies to be optimal for measuring VE and
accounting for bias and confounding.47 Adjusted rate
ratios of VE for prevention of hospitalisation/death/
general practice consultation will be derived from time-
dependent Cox models, taking into account the time at
risk and the possibility of multiple events (not for
death). Models will include a cluster term to account for
intrapractice correlation. These models will adjust for
gender, age, deprivation and clinical risk group and
exposure to vaccination in each season included as a
time-dependent covariate. Each season, individuals will
begin in the unvaccinated group (and will accumulate
time at risk) until 14 days after the receipt of the
vaccine; then they will switch to the vaccinated group.
In all models used to estimate the VE, we will adjust
for variables associated with the receipt of a vaccination
and effect modiﬁers, such as vaccinations, consultations
and hospitalisation in the previous inﬂuenza season,
SIMD, urban/rural status, smoking status, Charlson
score and pregnancy.
Sample size
We expect a ﬁnal total sample size of up to 1.25 million
from 220 practices. Using data from the PIPER 2014/
2015 cohort, which has 263 000 individuals, 16% are
aged 2–17, and 18% aged 65+.48 Vaccine uptake among
children aged 3–12 years is 60% and vaccine uptake
among those aged 65+ is 70%. Linked to this cohort
from all virology tests in Scotland were 1745 RT-PCR
tests overall; 331 RT-PCR tests among 2–17 years old; 366
RT-PCR tests among those aged 65+. This gives a multi-
plier ratio of around 5:1 from the PIPER cohort to the
SIVE II cohort and this is used to estimate the numbers
of RT-PCR tests expected each year. We expect 1800
RT-PCR tests per year among those aged 65+, 1650
laboratory tests per year among those aged 2–17. We
expect 1745/12×5=630 patients with asthma swabbed
per year as about 12% of the population is treated for
asthma.
Using data generated from the SIVE project,49 we esti-
mate a vaccination rate of 60% among children targeted
for receipt of LAIV and a swab positivity rate of 20%
among the unvaccinated. This should give 90% power to
detect a VE of 31% based on 1650 swabs in one season.
Pooling data over two seasons give an estimated 3300
swabs in children eligible for vaccination and a 90%
power to detect a VE of 22%.
For 65+ year olds targeted for receipt of TIV where
there is a vaccination rate of 70% and a swab positivity
rate of 10% among the unvaccinated we anticipate an
80% power to detect a VE of 39% where we estimate
that there will be 1800 swabs each year in the later years.
During the peak inﬂuenza activity when swab positivity
might increase to 20% there is a 90% power to detect a
VE of 31%. About 1 in 12 of the population is treated
for asthma50 and we anticipate 1260 swabs among
patients with asthma in ﬁnal two seasons. Assuming 40%
are vaccinated and that the swab positivity is around
15% gives 80% power for a VE of 35%. For an inﬂuenza
type/subtype which has 50% of the total cases, then the
detectable VEs will be 40–50% with 90% power. For a
type/subtype which has about 25% of the cases, then
the detectable VEs will increase to over 60% with 90%
power. These powers above do not take into account
design effects for the clustering of patients within GP
practices. Analyses of the historic PIPER cohorts48 has
revealed design effect of <7% and this serves to increase
the detectable VE by about two percentage points.
Dissemination
The study ﬁndings will be presented at international
conferences and published in peer-reviewed journals
(STROBE and RECORD will be used to guide transpar-
ent reporting).
Author affiliations
1Asthma UK Centre for Applied Research, Usher Institute of Population Health
Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
2Department of Mathematics and Statistics, University of Strathclyde,
Glasgow, UK
3Health Protection Scotland, Glasgow, UK
4Nuffield Department of Primary Care Health Sciences, Oxford University, New
Radcliffe House, Radcliffe Observatory Quarter, Oxford, UK
5Cardiff University, Institute of Primary Care and Public Health, Cardiff, UK
6Centre of Academic Primary Care, University of Aberdeen, UK
6 Simpson CR, et al. BMJ Open 2017;7:e014200. doi:10.1136/bmjopen-2016-014200
Open Access
7West of Scotland Specialist Virology Centre, Glasgow, UK
8Child Life & Health and MRC-Centre for Inflammation Research, The
University of Edinburgh, Edinburgh, UK
Contributors CRS, NIL, KK, CR, JM, BVM, LDR, RG and AS contributed to
the conception of the study. All authors contributed to the study design. All
authors contributed to drafting the protocol. All authors revised the
manuscript for important intellectual content. All authors gave final approval
of the version to be published.
Funding This project was funded by the National Institute for Health Research
Health Technology Assessment Programme (project number 13/34/14). EV was
supported by the Chief Scientist Office of the Scottish Government under grant
(AUKCAR/14/03). This work is carried out with the support of the Asthma UK
Centre for Applied Research (AUK-AC-2012–2001) and the Farr Institute.
Disclaimer The views and opinions expressed therein are those of the
authors and do not necessarily reflect those of the Health Technology
Assessment programme, NIHR, NHS or the Department of Health.
Competing interests None declared.
Ethics approval National Research Ethics Service Committee, West Midlands
—Edgbaston.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated
with influenza and respiratory syncytial virus in the United States.
JAMA 2003;289:179–86.
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual
impact of seasonal influenza in the US: measuring disease burden
and costs. Vaccine 2007;25:5086–96.
3. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory
infections due to seasonal influenza in young children: a systematic
review and meta-analysis. Lancet 2011;378:1917–30.
4. Cauchemez S, Valleron AJ, Boëlle PY, et al. Estimating the impact
of school closure on influenza transmission from sentinel data.
Nature 2008;452:750–4.
5. Baguelin M, Flasche S, Camacho A, et al. Assessing optimal target
populations for influenza vaccination programmes: an evidence
synthesis and modelling study. PLoS Med 2013;10:e1001527.
6. Department of Health. CVI statement on the routine annual influenza
vaccination programme https://www.gov.uk/government/publications/
jcvi-statement-on-the-routine-annual-influenza-vaccination-
programme (accessed 1 Jul 2016).
7. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and
effectiveness of influenza vaccines: A systematic review and
meta-analysis. Lancet Infect Dis 2012;12:36–44.
8. Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing
influenza in healthy children. Cochrane Database Syst Rev 2012;(8):
CD004879.
9. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing
influenza in healthy adults. Cochrane Database Syst Rev 2010;(7):
CD001269.
10. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention
of seasonal influenza in patients with diabetes: systematic review
and meta-analysis. BMC Med 2015;13:53.
11. Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of influenza
vaccination for preventing influenza-related complications in people
with asthma: a systematic review protocol. BMJ Open 2016;6:
e010133.
12. Valenciano M, Ciancio B. I-MOVE study team I-MOVE: a European
network to measure the effectiveness of influenza vaccines. Euro
Surveill 2012;17:pii:20281.
13. Doshi P. Influenza: marketing vaccine by marketing disease. BMJ
2013;346:f3037.
14. Simpson CR, Lone NI, Kavanagh K, et al. Trivalent inactivated
seasonal influenza vaccine effectiveness for the prevention of
laboratory confirmed influenza in a Scottish population 2000–2009.
Euro Surveill 2015;20:pii=21043.
15. Kavanagh K, Robertson C, McMenamin J. Assessment of the
variability in influenza A(H1N1) vaccine effectiveness estimates
dependent on outcome and methodological approach. PLoS ONE
2011;6:e28743.
16. Kavanagh K, Robertson C, McMenamin J. Estimates of influenza
vaccine effectiveness in primary care in Scotland vary with clinical or
laboratory endpoint and method—experience across the 2010/11
season. Vaccine 2013;31:4556–63.
17. Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated
influenza vaccine in atopic children with egg allergy. J Allergy Clin
Immunol 2015;136:376–81.
18. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control
of seasonal influenza with vaccines. MMWR Recomm Rep
2016;65:1–54.
19. De Serres G, Skowronski DM, Wu XW, et al. The test-negative
design: validity, accuracy and precision of vaccine efficacy estimates
compared to the gold standard of randomised placebo-controlled
clinical trials. Euro Surveill 2013;18:20585.
20. Information Services Division. Practice Team Information (PTI)
statistics. National Services Scotland, 2010.
21. McAlister FA, Murphy NF, Simpson CR, et al. Influence of
socioeconomic deprivation on the primary care burden and
treatment of patients with a diagnosis of heart failure in general
practice in Scotland: population based study. BMJ 2004;328:1110.
22. Whitelaw FG, Nevin SL, Milne RM, et al. Completeness and
accuracy of morbidity and repeat prescribing records held on general
practice computers in Scotland. Br J Gen Pract 1996;46:181–6.
23. ISD Scotland. Scottish Immunisation & Recall System. http://www.
isdscotland.org/Health-Topics/Child-Health/
Child-Health-Programme/Scottish-Immunisation-Recall-System.asp
(accessed 01 Sep 2016).
24. Health Protection Scotland. Surveillance data and systems. http://
www.hps.scot.nhs.uk/surveillance/SystemsDetail.aspx?id=248
(accessed 17 Jun 2016).
25. Information Services Division. NHS hospital data quality: towards
better data from Scottish hospitals. Edinburgh: ISD Publications
Scotland, 2007.
26. Kendrick S, Clarke J. The Scottish Record Linkage System. Health
Bull (Edinb) 1993;51:72–9.
27. Scottish Public Health Observatory. Overview of key data sources.
ISD linked database, 2010.
28. Health Protection Scotland. Influenza surveillance systems. http://
www.hps.scot.nhs.uk/resp/influenzasurveillancesystems.
aspx#seasons. (accessed 23 Nov 2015).
29. Chief Medical Officer. Seasonal influenza vaccination programme
2015-16. SGHD/CMO(2015)13. Scottish Government, 2015.
30. Department of Health Influenza (updated November 2011). In:
Salisbury D, Ramsay M, Noakes K, eds. Immunisation against
infectious disease. London: The Stationary Office, 2006:185–204.
31. National Statistics. Scottish Index of Multiple Deprivation: 2009
general report. Edinburgh: Scottish Government National Statistics
Publications, 2009.
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chron Dis 1987;40:373–83.
33. Schneeweiss S, Maclure M. Use of comorbidity scores for control of
confounding in studies using administrative databases. Int
J Epidemiol 2000;29:891–8.
34. Khan NF, Perera R, Harper S, et al. Adaptation and validation of the
Charlson Index for Read/OXMIS coded databases. BMC Fam Pract
2010;11:1.
35. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of
repeated vaccination on vaccine effectiveness against influenza A
(H3N2) and B during 8 seasons. Clin Infect Dis 2014;59:
1375–85.
36. Skowronski DM, Chambers C, Sabaiduc S, et al. A perfect storm:
impact of genomic variation and serial vaccination on low influenza
vaccine effectiveness during the 2014-15 season. Clin Infect Dis
2016;63:21–32.
37. Wallace LA, McAulay KA, Douglas JD, et al. Influenza diagnosis:
from dark isolation into the molecular light. West of Scotland
Respiratory Virus Study Group. J Infect 1999;39:221–6.
38. Gunson RN, Bennett S, Maclean A, et al. Using multiplex real time
PCR in order to streamline a routine diagnostic service. J Clin Virol
2008;43:372–5.
39. Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and
neuropsychiatric risks of varenicline: a retrospective cohort study.
Lancet Respir Med 2015;3:761–8.
40. Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of
influenza vaccination in elderly people: an ongoing controversy.
Lancet Infect Dis 2007;7:658–66.
Simpson CR, et al. BMJ Open 2017;7:e014200. doi:10.1136/bmjopen-2016-014200 7
Open Access
41. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of
regression results to unmeasured confounders in observational
studies. Biometrics 1998;54:948–63.
42. Wong K, Campitelli MA, Stukel TA, et al. Estimating influenza
vaccine effectiveness in community-dwelling elderly patients using
the instrumental variable analysis method. Arch Intern Med
2012;172:484–91.
43. Greenland S. An introduction to instrumental variables for
epidemiologists. Int J Epidemiol 2000;29:722–9.
44. Glanz JM, McClure DL, Xu S, et al. Four different study designs to
evaluate vaccine safety were equally validated with contrasting
limitations. J Clin Epidemiol 2006;59:808–18.
45. Farrington CP. Control without separate controls: evaluation of
vaccine safety using case-only methods. Vaccine 2004;22:2064–70.
46. Vellozzi C, Burwen DR, Dobardzic A, et al. Safety of trivalent
inactivated influenza vaccines in adults: background for
pandemic influenza vaccine safety monitoring. Vaccine
2009;27:2114–20.
47. Lone N, Simpson CR, Ritchie LD, et al. Seasonal Influenza Vaccine
Effectiveness in the community (SIVE): exploitation of a unique
national linked dataset. BMJ Open 2012;15:e001019.
48. Health Protection Scotland. Influenza surveillance systems. http://
www.hps.scot.nhs.uk/resp/influenzasurveillancesystems.aspx#piper
(accessed 1 Sep 2016).
49. Simpson CR, Lone N, Kavanagh K, et al. Seasonal influenza
vaccine effectiveness (SIVE): an observational retrospective cohort
study—exploitation of a unique community-based national-linked
database to determine the effectiveness of the seasonal trivalent
influenza vaccine. Health Serv Deliv Res 2013;1:1–46.
50. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in
England: a national study of 333,294 patients. J R Soc Med
2010;103:98–106.
8 Simpson CR, et al. BMJ Open 2017;7:e014200. doi:10.1136/bmjopen-2016-014200
Open Access
